Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. cut its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 16.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 730,955 shares of the company’s stock after selling 142,606 shares during the period. Federated Hermes Inc. owned about 0.34% of Hims & Hers Health worth $14,758,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC raised its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the second quarter valued at about $111,000. Belpointe Asset Management LLC raised its position in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after buying an additional 1,205 shares during the last quarter. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Hims & Hers Health in the second quarter valued at about $142,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $16.30 on Tuesday. The stock has a market capitalization of $3.50 billion, a PE ratio of -1,630.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The company’s 50-day simple moving average is $17.71 and its 200-day simple moving average is $17.03.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s quarterly revenue was up 51.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 45,755 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $22.97, for a total value of $1,050,992.35. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $769,540.94. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Andrew Dudum sold 45,755 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $22.97, for a total value of $1,050,992.35. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $769,540.94. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 752,820 shares of company stock valued at $13,545,954. 17.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Citigroup cut shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their target price for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Piper Sandler reissued a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Bank of America dropped their price objective on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.